AI Article Synopsis

  • - Hypertension is a leading cause of heart disease and death globally, and low-dose combination therapy using amlodipine, telmisartan, and chlorthalidone shows promise for safe and effective management according to a systematic review.
  • - The review analyzed randomized controlled trials (RCTs) to assess the effectiveness of this combination therapy, focusing on changes in blood pressure and adverse effects, finding three RCTs that met quality standards.
  • - Results indicated significant improvements in blood pressure control and a low risk of serious side effects; however, variations in dosages and control groups suggest further research is necessary to fully understand the long-term outcomes and factors influencing treatment responses.

Article Abstract

Hypertension is a major cause of cardiovascular disease and death worldwide. Low-dose combination therapy is a promising approach for managing hypertension due to its safety and efficacy. This systematic review evaluates the safety and efficacy of a single-pill, low-dose combination of amlodipine, telmisartan, and chlorthalidone for essential hypertension based on evidence from randomized controlled trials (RCTs). We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and searched the Cochrane, Scopus, PubMed, and Web of Science databases until July 01, 2024, using the following search string: (telmisartan) AND (amlodipine) AND (chlorthalidone) AND (randomized OR randomly). The quality of the RCTs was assessed using the revised Cochrane risk of bias tool. The primary endpoint was the mean change in sitting systolic blood pressure (BP), with secondary endpoints including BP target achievement rates, BP response rates, and serious treatment-related adverse events. Overall, three RCTs met the inclusion criteria and exhibited a low risk of bias. The doses in the combination pill ranged from 2.5 to 5 mg of amlodipine, 20 to 80 mg of telmisartan, and 4.167 to 25 mg of chlorthalidone. Control groups varied, including usual care, amlodipine 10 mg, and dual therapy of telmisartan and amlodipine. Results showed significant reductions in mean sitting systolic and diastolic BP, improved BP control and response rates, and a generally safe profile with no significant differences in serious adverse events. Despite encouraging data, results should be interpreted with caution due to heterogeneity in doses and control groups. Further research should address the long-term effects and explore predictors of response to this therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456305PMC
http://dx.doi.org/10.7759/cureus.68802DOI Listing

Publication Analysis

Top Keywords

amlodipine telmisartan
12
combination therapy
8
telmisartan chlorthalidone
8
systematic review
8
randomized controlled
8
controlled trials
8
low-dose combination
8
safety efficacy
8
telmisartan amlodipine
8
risk bias
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!